Marché mondial des services de sécurité cardiaque, par services (mesures ECG/Holter, mesures de la pression artérielle , services d'évaluation de la sécurité cardiaque in vitro, imagerie cardiovasculaire, surveillance télémétrique en temps réel, surlecture centrale de l'ECGS, imagerie cardiaque non invasive, tests de stress physiologique, études approfondies du QT, modélisation du TQT et de la réponse à l'exposition, agrégation plaquettaire et autres services), phase (phase 1, phase 2 et phase 3), type (services intégrés et services autonomes), utilisateur final ( sociétés pharmaceutiques et biopharmaceutiques, organismes de recherche sous contrat et instituts universitaires et de recherche) Tendances et prévisions de l'industrie jusqu'en 2029.
Analyse et perspectives du marché
Le marché mondial des services de sécurité cardiaque est stimulé par des facteurs tels que l'augmentation du développement de nouveaux médicaments, le nombre croissant d'acteurs émergents et l'innovation technologique, qui augmentent sa demande, ainsi que l'augmentation des investissements dans la recherche et le développement, conduisant à la croissance du marché. Actuellement, diverses études de recherche sont en cours, ce qui devrait créer un avantage concurrentiel pour les fabricants afin de développer des systèmes de services de sécurité cardiaque nouveaux et innovants, ce qui devrait offrir diverses autres opportunités sur le marché des services de sécurité cardiaque. Cependant, les réglementations gouvernementales strictes en matière d'approbation devraient entraver la croissance.
Le rapport sur le marché mondial des services de sécurité cardiaque fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et localisé, analyse les opportunités en termes de poches de revenus émergentes, les changements dans la réglementation du marché, les approbations de produits, les décisions stratégiques, les lancements de produits, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité. L'évolutivité et l'expansion commerciale des unités de vente au détail dans les pays en développement de diverses régions et le partenariat avec les fournisseurs pour une distribution sûre de machines et de produits pharmaceutiques sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
Le marché mondial des services de sécurité cardiaque est favorable et vise à réduire la progression de la maladie. Data Bridge Market Research analyse que le marché mondial des services de sécurité cardiaque connaîtra un TCAC de 15,4 % au cours de la période de prévision de 2022 à 2029.
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Années historiques |
2020 (personnalisable de 2019 à 2014) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, prix en USD |
|
Segments couverts |
Par services (mesures ECG/Holter, mesures de la pression artérielle, services d'évaluation de la sécurité cardiaque in vitro, imagerie cardiovasculaire, surveillance télémétrique en temps réel, sur-lecture centralisée de l'ECGS, imagerie cardiaque non invasive, tests de stress physiologique, études approfondies du QT, modélisation du TQT et de la réponse à l'exposition, agrégation plaquettaire et autres services), phase (phase 1, phase 2 et phase 3), type (services intégrés et services autonomes), utilisateur final (sociétés pharmaceutiques et biopharmaceutiques, organismes de recherche sous contrat et instituts universitaires et de recherche) |
|
Pays couverts |
États-Unis, Canada, Mexique, Brésil, Argentine et reste de l'Amérique du Sud, Afrique du Sud, Arabie saoudite, Émirats arabes unis, Israël, Égypte et reste du Moyen-Orient et de l'Afrique, Allemagne, France, Royaume-Uni, Italie, Espagne, Turquie, Russie, Pays-Bas, Suisse, Belgique et reste de l'Europe, Chine, Japon, Corée du Sud, Inde, Australie, Singapour, Thaïlande, Malaisie, Indonésie, Philippines et reste de l'Asie-Pacifique |
|
Acteurs du marché couverts |
Royal Philips NV, Laboratory Corporation of America Holdings, IQVIA, Medpace, Ncardia, Certara, Eurofins Scientific, SGS SA, Banook, Celerion, Biotrial, NEXEL Co., Ltd, Richmond Pharmacology, PhysioStim, Shanghai Medicilon Inc, Clario, PPD Inc entre autres. |
Définition du marché
Les services de sécurité cardiaque aident généralement à soutenir et à concevoir des essais cliniques et d'autres recherches nécessaires pour surveiller la sécurité cardiaque. La demande pour le marché des services de sécurité cardiaque a augmenté dans les pays développés comme dans les pays en développement, en raison du nombre croissant d'essais cliniques et de lancements de produits. Le marché des services de sécurité cardiaque est en croissance en raison de l'introduction de produits innovants, de l'augmentation des produits technologiques et de l'augmentation du revenu disponible. Le marché va croître au cours de la période prévue en raison de l'exploration des marchés émergents, des initiatives stratégiques des acteurs du marché et de l'augmentation des dépenses de santé.
Dynamique du marché mondial des services de sécurité cardiaque
Conducteurs
- Augmentation du nombre d’essais cliniques
Un essai clinique est un système bien structuré qui existe depuis des centaines d’années et qui constitue toujours l’épine dorsale des exigences réglementaires requises pour qu’un médicament soit approuvé. Récemment, de nombreuses avancées ont été réalisées dans le domaine des essais cliniques, ce qui a augmenté le nombre d’essais cliniques et devrait propulser la croissance du marché.
Il y a eu divers changements dans la réglementation des essais cliniques , ce qui a augmenté le nombre d'essais cliniques et leurs résultats positifs.
Par exemple,
- Selon l'article de Medical News, le nombre d'essais cliniques a considérablement augmenté en raison de l'amélioration de la qualité des essais cliniques, notamment grâce à la formation obligatoire de tout le personnel. En outre, en 2017, le NIH a déclaré que tous les enquêteurs et le personnel devraient être formés aux bonnes pratiques cliniques (BPC) dans les essais financés par le NIH
Augmentation des dépenses et du financement des soins de santé
L’ampleur des dépenses consacrées par un pays aux soins de santé et son taux de croissance au fil du temps sont influencés par une grande variété de facteurs économiques et sociaux, notamment les modalités de financement et la structure de l’organisation du système de santé.
Les dépenses de santé ont augmenté dans les pays développés et les économies émergentes en raison de l'augmentation du revenu disponible des citoyens. Plus les dépenses de santé sont élevées, plus la population d'un pays est en bonne santé.
Opportunité
- Augmentation du développement de nouveaux médicaments
Les essais cliniques sont essentiels pour découvrir et développer de nouveaux médicaments pour le traitement des maladies. C'est le meilleur moyen pour les chercheurs de découvrir quels traitements fonctionnent ou non sur les humains. Le développement de médicaments se caractérise par la mise au point de nouveaux traitements sous forme de médicaments ou de dispositifs pour guérir diverses maladies telles que le cancer, les maladies endocriniennes, métaboliques et autres.
- Ainsi, les essais cliniques sont le moyen le plus efficace de garantir la sécurité et l'efficacité du médicament thérapeutique avant son lancement sur le marché et la consommation humaine, ce qui inclut l'évaluation de la sécurité cardiaque, qui est une partie essentielle avant la mise sur le marché de tout produit médical.
Retenue/Défi
L'évaluation et la communication appropriées des données cliniques sur la sécurité cardiaque sont essentielles. L'approbation et le rappel de tout produit médical dépendent de l'évaluation de la sécurité cardiaque. Il est donc nécessaire de fournir et de mener une évaluation de la sécurité cardiaque conformément à la procédure légale, sinon cela conduit à une approbation tardive du produit, ce qui devrait freiner la croissance du marché.
Par exemple,
- Selon l'article d'IQVIA, il y a eu 47 cas de retrait post-commercialisation de médicaments entre 1957 et 2007, dont 45 % en raison de préoccupations concernant la toxicité cardiovasculaire. De même, 27 % des nouvelles molécules médicamenteuses potentielles qui ont échoué en phase préclinique au cours des deux dernières décennies l'ont fait en raison de la toxicité cardiovasculaire, car elles ne répondaient pas aux exigences réglementaires requises.
Segmentation du marché mondial des services de sécurité cardiaque
Le marché mondial des services de sécurité cardiaque est classé en types, services, phases et utilisateurs finaux. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
Services
- Mesures ECG /Holter
- Mesures de la pression artérielle
- Services d’évaluation de la sécurité cardiaque in vitro
- Imagerie cardiovasculaire
- Surveillance de la télémétrie en temps réel
- Lecture centralisée de l'ECGS
- Imagerie cardiaque non invasive
- Test de stress physiologique
- Études approfondies du QT
- TQT et modélisation de la réponse à l'exposition
- Agrégation plaquettaire
- Autres services
Sur la base des services, le marché des services de sécurité cardiaque est segmenté en mesures ECG/Holter, mesures de la pression artérielle, services d'évaluation de la sécurité cardiaque in vitro, imagerie cardiovasculaire, surveillance télémétrique en temps réel, surlecture centrale de l'ECGS, imagerie cardiaque non invasive, tests de stress physiologique, études approfondies du QT, modélisation de la réponse à l'exposition et du TQT, agrégation plaquettaire et autres services.
Phase
- Phase 1
- Phase 2
- Phase 3
Sur la base des phases, le marché des services de sécurité cardiaque est segmenté en phase 1, phase 2 et phase 3.
Taper
- Services intégrés
- Services autonomes
Sur la base du type, le marché des services de sécurité cardiaque est segmenté en services intégrés et services autonomes.
Utilisateur final
- Sociétés pharmaceutiques et biopharmaceutiques
- Organismes de recherche sous contrat
- Institut universitaire et de recherche
Sur la base de l'utilisateur final, le marché des services de sécurité cardiaque est segmenté en sociétés pharmaceutiques et biopharmaceutiques, en organismes de recherche sous contrat et en instituts universitaires et de recherche.
Analyse et aperçus régionaux des services de sécurité cardiaque
Les services de sécurité cardiaque sont analysés et des informations sur la taille du marché et les tendances sont fournies par type, services, phase et utilisateur final, comme référencé ci-dessus.
Les pays couverts par le rapport sur les services de sécurité cardiaque sont les suivants : États-Unis, Canada, Mexique, Brésil, Argentine et reste de l'Amérique du Sud, Afrique du Sud, Arabie saoudite, Émirats arabes unis, Israël, Égypte et reste du Moyen-Orient et de l'Afrique, Allemagne, France, Royaume-Uni, Italie, Espagne, Turquie, Russie, Pays-Bas, Suisse, Belgique et reste de l'Europe, Chine, Japon, Corée du Sud, Inde, Australie, Singapour, Thaïlande, Malaisie, Indonésie, Philippines et reste de l'Asie-Pacifique
Les États-Unis devraient dominer le marché en raison de l’augmentation des progrès technologiques dans les régions en développement.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces du porteur, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des services de sécurité cardiaque
Le paysage concurrentiel du marché mondial des services de sécurité cardiaque fournit des détails par concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché des services de sécurité cardiaque.
Certains des principaux acteurs du marché sont Koninklijke Philips NV, Laboratory Corporation of America Holdings, IQVIA, Medpace, Ncardia, Certara, Eurofins Scientific, SGS SA, Banook, Celerion, Biotrial, NEXEL Co., Ltd, Richmond Pharmacology, PhysioStim, Shanghai Medicilon Inc, Clario, PPD Inc entre autres.
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse mondiale par rapport aux régions et la part des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CARDIAC SAFETY SERVICES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6 INDUSTRY INSIGHT
6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.2 PATENT ANALYSIS
6.3 PATENT FLOW DIAGRAM
6.4 KEY PATIENT ENROLLMENT STRATEGIES
6.5 PRICING STRATEGY
7 GLOBAL CARDIAC SAFETY SERVICES MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS
8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING
8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS
8.1.4 INCREASE IN R&D ACTIVITIES
8.2 RESTRAINTS
8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION
8.2.2 STRICT REGULATORY
8.3 OPPORTUNITIES:
8.3.1 INCREASE IN NEW DRUG DEVELOPMENT
8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES
8.4 CHALLENGES
8.4.1 TIME-CONSUMING PROCEDURE
8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION
9 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY SERVICES
9.1 OVERVIEW
9.2 ECG/HOLTER MEASUREMENTS
9.3 BLOOD PRESSURE MEASUREMENTS
9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES
9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS
9.4.1.1 1 CONCENTRATIONS
9.4.1.2 4 CONCENTRATIONS
9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA)
9.4.2.1 3 CONCENTRATIONS
9.4.2.2 5 CONCENTRATIONS
9.4.3 IN VITRO HERG ASSAY
9.4.4 OTHERS
9.5 CARDIOVASCULAR IMAGING
9.6 REAL TIME TELEMETRY MONITORING
9.7 CENTRAL OVER-READ OF ECGS
9.8 NON-INVASIVE CARDIAC IMAGING
9.9 PHYSIOLOGIC STRESS TESTING
9.1 THOROUGH QT STUDIES
9.11 TQT AND EXPOSURE RESPONSE MODELLING
9.12 PLATELET AGGREGATION
9.13 OTHERS
10 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY PHASE
10.1 OVERVIEW
10.2 PHASE I
10.3 PHASE II
10.4 PHASE III
11 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY TYPE
11.1 OVERVIEW
11.2 INTEGRATED SERVICES
11.3 STANDALONE SERVICES
12 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY END USER
12.1 OVERVIEW
12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES
12.3 CONTRACT RESEARCH ORGANIZATIONS
12.4 ACADEMIC AND RESEARCH INSTITUTE
13 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY REGION
13.1 OVERVIEW
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.2 CANADA
13.2.3 MEXICO
13.3 EUROPE
13.3.1 GERMANY
13.3.2 FRANCE
13.3.3 U.K.
13.3.4 ITALY
13.3.5 SPAIN
13.3.6 TURKEY
13.3.7 RUSSIA
13.3.8 NETHERLANDS
13.3.9 SWITZERLAND
13.3.10 BELGIUM
13.3.11 REST OF EUROPE
13.4 ASIA-PACIFIC
13.4.1 CHINA
13.4.2 JAPAN
13.4.3 SOUTH KOREA
13.4.4 INDIA
13.4.5 AUSTRALIA
13.4.6 SINGAPORE
13.4.7 THAILAND
13.4.8 MALAYSIA
13.4.9 INDONESIA
13.4.10 PHILIPPINES
13.4.11 REST OF ASIA-PACIFIC
13.5 SOUTH AMERICA
13.5.1 BRAZIL
13.5.2 ARGENTINA
13.5.3 REST OF SOUTH AMERICA
13.6 MIDDLE EAST AND AFRICA
13.6.1 SOUTH AFRICA
13.6.2 SAUDI ARABIA
13.6.3 U.A.E.
13.6.4 ISRAEL
13.6.5 EGYPT
13.6.6 REST OF MIDDLE EAST AND AFRICA
14 GLOBAL CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.3 COMPANY SHARE ANALYSIS: EUROPE
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 COMPANY PROFILE
15.1 EUROFINS SCIENTIFIC
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.1.5.1 AGREEMENTS
15.1.5.2 ACQUISITION
15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC)
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.2.5.1 INVESTMENT
15.3 KONINKLIJKE PHILIPS N.V.
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.3.5.1 ACQUISITION
15.4 IQVIA
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.4.5.1 ACQUISITION
15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.5.5.1 NEW LABORATORY
15.5.5.2 ACQUISITION
15.6 BANOOK
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.6.3.1 AGREEMENT
15.7 BIOTRIAL
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.7.3.1 NEW CENTER OPENING
15.8 CELERION
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.8.3.1 NEW CENTER OPENING
15.9 CERTARA
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.9.4.1 CONTRACT
15.9.4.2 ACQUISITION
15.1 CLARIO
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.10.3.1 PRODUCT EXPANSION
15.11 MEDPACE
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENTS
15.11.4.1 ACQUISITION
15.12 NCARDIA
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.12.3.1 PARTNERSHIP
15.13 NEXEL CO., LTD
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENTS
15.13.3.1 JOINT VENTURE
15.13.3.2 PARTNERSHIP
15.14 PHYSIOSTIM
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.14.3.1 PARTNERSHIP
15.15 RICHMOND PHARMACOLOGY
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.15.3.1 EVENT
15.16 SGS SA
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.16.4.1 ACQUISITION
15.17 SHANGHAI MEDICILON INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENTS
15.17.3.1 PARTNERSHIP
15.17.3.2 PARTNERSHIP
16 QUESTIONNAIRE
17 RELATED REPORTS
Liste des tableaux
TABLE 1 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE
TABLE 2 PROBABILITY OF SUCCESS BY CLINICAL TRIAL PHASE TO THERAPEUTIC AREA
TABLE 3 MORTALITY RATES FROM CLINICAL TRIALS AND EUROPEAN SAFETY AND EXPOSURE SURVEY (ESES), DEATHS PER 100 (PYE)
TABLE 4 ADHERENCE RATE TO COMMON CARDIOVASCULAR MEDICATION
TABLE 5 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE
TABLE 6 INITIATIVES TO INCREASE ENROLLMENT IN CLINICAL TRIALS AMONG UNDERREPRESENTED POPULATIONS
TABLE 7 ESTIMATED COST OF CARDIAC SAFETY EVALUATION DEVICES
TABLE 8 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 9 GLOBAL ECG/HOLTER MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 GLOBAL BLOOD PRESSURE MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 GLOBAL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 GLOBAL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 13 GLOBAL HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 14 GLOBAL COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 15 GLOBAL CARDIOVASCULAR IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 GLOBAL REAL TIME TELEMETRY MONITORING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 GLOBAL CENTRAL OVER-READ OF ECGS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 GLOBAL NON-INVASIVE CARDIAC IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 GLOBAL PHYSIOLOGIC STRESS TESTING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 GLOBAL THOROUGH QT STUDIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 GLOBAL TQT AND EXPOSURE RESPONSE MODELLING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 GLOBAL PLATELET AGGREGATION IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 GLOBAL OTHERS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 25 GLOBAL PHASE I IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 GLOBAL PHASE II IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 GLOBAL PHASE III IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 GLOBAL INTEGRATED SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 GLOBAL STANDALONE SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 GLOBAL PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 GLOBAL CONTRACT RESEARCH ORGANIZATIONS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 GLOBAL ACADEMIC AND RESEARCH INSTITUTE IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 U.S. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 45 U.S. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 46 U.S. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 47 U.S. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 48 U.S. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 49 U.S. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 U.S. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 CANADA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 52 CANADA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 53 CANADA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 54 CANADA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 55 CANADA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 56 CANADA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 CANADA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 58 MEXICO CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 59 MEXICO IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 60 MEXICO HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 61 MEXICO COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 62 MEXICO CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 63 MEXICO CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 MEXICO CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 EUROPE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 66 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 67 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 68 EUROPE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 69 EUROPE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 70 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 71 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 73 GERMANY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 74 GERMANY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 75 GERMANY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 76 GERMANY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 77 GERMANY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 78 GERMANY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 GERMANY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 80 FRANCE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 81 FRANCE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 82 FRANCE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 83 FRANCE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 84 FRANCE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 85 FRANCE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 FRANCE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 87 U.K. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 88 U.K. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 89 U.K. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 90 U.K. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 91 U.K. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 92 U.K. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 U.K. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 ITALY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 95 ITALY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 96 ITALY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 97 ITALY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 98 ITALY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 99 ITALY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 ITALY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 101 SPAIN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 102 SPAIN IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 103 SPAIN HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 104 SPAIN COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 105 SPAIN CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 106 SPAIN CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 SPAIN CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 108 TURKEY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 109 TURKEY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 110 TURKEY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 111 TURKEY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 112 TURKEY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 113 TURKEY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 TURKEY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 115 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 116 RUSSIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 117 RUSSIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 118 RUSSIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 119 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 120 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 122 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 123 NETHERLANDS IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 124 NETHERLANDS HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 125 NETHERLANDS COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 126 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 127 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 129 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 130 SWITZERLAND IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 131 SWITZERLAND HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 132 SWITZERLAND COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 133 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 134 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 135 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 136 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 137 BELGIUM IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 138 BELGIUM HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 139 BELGIUM COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 140 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 141 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 143 REST OF EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 144 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 145 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 146 ASIA-PACIFIC IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 147 ASIA-PACIFIC HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 148 ASIA-PACIFIC COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 149 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 150 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 152 CHINA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 153 CHINA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 154 CHINA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 155 CHINA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 156 CHINA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 157 CHINA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 CHINA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 159 JAPAN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 160 JAPAN IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 161 JAPAN HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 162 JAPAN COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 163 JAPAN CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 164 JAPAN CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 165 JAPAN CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 166 SOUTH KOREA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 167 SOUTH KOREA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 168 SOUTH KOREA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 169 SOUTH KOREA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 170 SOUTH KOREA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 171 SOUTH KOREA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 SOUTH KOREA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 173 INDIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 174 INDIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 175 INDIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 176 INDIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 177 INDIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 178 INDIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 INDIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 180 AUSTRALIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 181 AUSTRALIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 182 AUSTRALIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 183 AUSTRALIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 184 AUSTRALIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 185 AUSTRALIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 186 AUSTRALIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 187 SINGAPORE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 188 SINGAPORE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 189 SINGAPORE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 190 SINGAPORE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 191 SINGAPORE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 192 SINGAPORE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 SINGAPORE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 194 THAILAND CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 195 THAILAND IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 196 THAILAND HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 197 THAILAND COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 198 THAILAND CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 199 THAILAND CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 THAILAND CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 201 MALAYSIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 202 MALAYSIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 203 MALAYSIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 204 MALAYSIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 205 MALAYSIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 206 MALAYSIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 MALAYSIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 208 INDONESIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 209 INDONESIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 210 INDONESIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 211 INDONESIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 212 INDONESIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 213 INDONESIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 214 INDONESIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 215 PHILIPPINES CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 216 PHILIPPINES IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 217 PHILIPPINES HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 218 PHILIPPINES COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 219 PHILIPPINES CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 220 PHILIPPINES CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 PHILIPPINES CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 222 REST OF ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 223 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 224 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 225 SOUTH AMERICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 226 SOUTH AMERICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 227 SOUTH AMERICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 228 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 229 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 231 BRAZIL CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 232 BRAZIL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 233 BRAZIL HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 234 BRAZIL COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 235 BRAZIL CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 236 BRAZIL CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 BRAZIL CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 238 ARGENTINA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 239 ARGENTINA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 240 ARGENTINA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 241 ARGENTINA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 242 ARGENTINA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 243 ARGENTINA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 244 ARGENTINA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 245 REST OF SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 246 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 247 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 248 MIDDLE EAST AND AFRICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 249 MIDDLE EAST AND AFRICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 250 MIDDLE EAST AND AFRICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 251 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 252 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 253 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 254 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 255 SOUTH AFRICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 256 SOUTH AFRICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 257 SOUTH AFRICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 258 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 259 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 260 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 261 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 262 SAUDI ARABIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 263 SAUDI ARABIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 264 SAUDI ARABIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 265 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 266 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 267 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 268 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 269 U.A.E. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 270 U.A.E. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 271 U.A.E. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 272 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 273 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 274 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 275 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 276 ISRAEL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 277 ISRAEL HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 278 ISRAEL COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 279 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 280 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 281 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 282 EGYPT CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 283 EGYPT IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 284 EGYPT HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 285 EGYPT COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 286 EGYPT CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 287 EGYPT CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 288 EGYPT CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 289 REST OF MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 GLOBAL CARDIAC SAFETY SERVICES MARKET: SEGMENTATION
FIGURE 2 GLOBAL CARDIAC SAFETY SERVICES MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL CARDIAC SAFETY SERVICES MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL CARDIAC SAFETY SERVICES MARKET: GLOBAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 GLOBAL CARDIAC SAFETY SERVICES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL CARDIAC SAFETY SERVICES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL CARDIAC SAFETY SERVICES MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL CARDIAC SAFETY SERVICES MARKET: MARKET END USER GRID
FIGURE 9 GLOBAL CARDIAC SAFETY SERVICES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL CARDIAC SAFETY SERVICES MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN DEMAND FOR CARDIAC SAFETY SERVICES ARE EXPECTED TO DRIVE THE GLOBAL CARDIAC SAFETY SERVICES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 ECG/HOLTER MEASUREMENTS SUBSTITUTE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CARDIAC SAFETY SERVICES MARKET IN 2022 & 2029
FIGURE 13 PATIENT FLOW DIAGRAM FOR ANY RANDOM DRUG
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL CARDIAC SAFETY SERVICES MARKET
FIGURE 15 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2021
FIGURE 16 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2022-2029 (USD MILLION)
FIGURE 17 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES, CAGR (2022-2029)
FIGURE 18 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES, LIFELINE CURVE
FIGURE 19 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2021
FIGURE 20 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2022-2029 (USD MILLION)
FIGURE 21 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY PHASE, CAGR (2022-2029)
FIGURE 22 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY PHASE, LIFELINE CURVE
FIGURE 23 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2021
FIGURE 24 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 25 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 26 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY END USER, 2021
FIGURE 28 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 29 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY END USER, CAGR (2022-2029)
FIGURE 30 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 GLOBAL CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 32 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY REGION (2021)
FIGURE 33 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY REGION (2022 & 2029)
FIGURE 34 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY REGION (2021 & 2029)
FIGURE 35 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 36 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 37 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)
FIGURE 38 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 39 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 40 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 41 EUROPE CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 42 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)
FIGURE 43 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 44 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 45 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 46 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 47 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)
FIGURE 48 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 49 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 50 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 51 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 52 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)
FIGURE 53 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 54 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 55 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 56 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 57 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)
FIGURE 58 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 59 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 60 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 61 GLOBAL CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)
FIGURE 62 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)
FIGURE 63 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)
FIGURE 64 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
